PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
April 18, 2026Journal of Clinical InvestigationOpen Access

Therapeutic targeting of the eIF4E cap-binding domain reveals control of lineage fate in prostate cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

RMRashmi MishraSSSihyeon SongDCDhruv Choradia

Discussion

Loading...

Member takes

Overview

Research reveals that targeting eIF4E improves outcomes in prostate cancer with lineage plasticity, suggesting new treatment strategies.

Key Points

  • This research aims to explore the role of the eIF4E cap-binding domain in regulating lineage plasticity in prostate cancer.
  • Identified the role of eIF4E using a cap-binding domain inhibitor
  • Analyzed translational repression of basal keratins and stabilization of androgen receptor
  • Studied the relationship between eIF4E expression and lineage fate in castration-resistant prostate cancer (CRPC) patients
  • Inhibition of eIF4E reprogrammed resistant tumors towards a luminal state
  • Elevated eIF4E levels correlated with reduced luminal differentiation in CRPC patients
  • The cap-binding domain regulates a lineage program essential for cell survival

Cite This Study

Mishra et al. (2026) studied this question.

synapsesocial.com/papers/69e31f1a40886becb653e848https://doi.org/10.1172/jci199838
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract PR032: Therapeutic targeting of eIF4E cap-binding domain reveals control of lineage fate in prostate cancer2026
  2. 2Rewriting the cancer proteome: targeting selective translation as a therapeutic frontier2026
  3. 3Abstract 2187: Direct regulation of the cancer stemness by eIF4A1 in triple-negative breast cancer.2026
  4. 43D Genome Architecture and Epigenetic Regulation of Lineage Identity in Advanced Prostate Cancer2026
  5. 5eIF4G2-Dependent Translation Restrains Pancreatic Cancer Progression2026